Nuevocor secures $24M for cardiac gene therapies

By The Science Advisory Board staff writers

June 18, 2021 -- Nuevocor has completed a $24 million financing round to accelerate the preclinical development of its lead program, an adeno-associated virus (AAV)-based gene therapy for patients with cardiomyopathy due to mutations in the lamin A/C (LMNA) gene.

Nuevocor is focused on developing AAV gene therapies, and its lead program is based on research conducted by scientific cofounders Colin Stewart, PhD and Brian Burke, PhD, of Singapore's Agency for Science, Technology and Research (A*STAR).

With gene therapy experience provided by cofounder Dr. Mark Kay, PhD, from Stanford University and cardiac disease modelling expertise provided by cofounder Jianming Jiang, PhD, from the National University of Singapore, the company also plans to target other untreatable cardiomyopathies using its novel target discovery platform.

The oversubscribed series A financing round was co-led by EVX Ventures and Boehringer Ingelheim Venture Fund (BIVF).

Copyright © 2021

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter